Related references
Note: Only part of the references are listed.MRI in early rheumatoid arthritis: synovitis and bone marrow oedema are independent predictors of subsequent radiographic progression
Pernille Boyesen et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Prediction of MRI erosive progression: a comparison of modern imaging modalities in early rheumatoid arthritis patients
Pernille Boyesen et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Exploratory analyses of the association of MRI with clinical, laboratory and radiographic findings in patients with rheumatoid arthritis
Paul Emery et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
The Effects of Golimumab on Radiographic Progression in Rheumatoid Arthritis Results of Randomized Controlled Studies of Golimumab Before Methotrexate Therapy and Golimumab After Methotrexate Therapy
Paul Emery et al.
ARTHRITIS AND RHEUMATISM (2011)
Significant improvement in synovitis, osteitis, and bone erosion following golimumab and methotrexate combination therapy as compared with methotrexate alone: A magnetic resonance imaging study of 318 methotrexate-naive rheumatoid arthritis patients
Mikkel Ostergaard et al.
ARTHRITIS AND RHEUMATISM (2011)
Radiographic progression and remission rates in early rheumatoid arthritis - MRI bone oedema and anti-CCP predicted radiographic progression in the 5-year extension of the double-blind randomised CIMESTRA trial
Merete L. Hetland et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Golimumab, a New Human Anti-Tumor Necrosis Factor α Antibody, Administered Intravenously in Patients With Active Rheumatoid Arthritis Forty-Eight-Week Efficacy and Safety Results of a Phase III Randomized, Double-Blind, Placebo-Controlled Study
Joel Kremer et al.
ARTHRITIS AND RHEUMATISM (2010)
MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2-year randomised controlled trial (CIMESTRA)
M. L. Hetland et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Golimumab, a Human Anti-Tumor Necrosis Factor α Monoclonal Antibody, Injected Subcutaneously Every Four Weeks in Methotrexate-Naive Patients With Active Rheumatoid Arthritis Twenty-Four-Week Results of a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Golimumab Before Methotrexate as First-Line Therapy for Early-Onset Rheumatoid Arthritis
Paul Emery et al.
ARTHRITIS AND RHEUMATISM (2009)
Magnetic resonance imaging findings in 84 patients with early rheumatoid arthritis: bone marrow oedema predicts erosive progression
E. A. Haavardsholm et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
New radiographic bone erosions in the wrists of patients with rheumatoid arthritis are detectable with magnetic resonance imaging a median of two years earlier
M Ostergaard et al.
ARTHRITIS AND RHEUMATISM (2003)
Share Paper
